Go Pro
→ ALERT: Drop these 5 stocks before the market opens tomorrow! (From Weiss Ratings) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Atrinsic Inc. stock logo
PTIX
Atrinsic
$0.32
-10.9%		$0.31
$0.13
▼
$6.20
$580K1.0829,810 shs2,477 shs
Silexion Therapeutics Corp stock logo
SLXN
Silexion Therapeutics
$0.42
-8.7%		$2.42
$0.37
▼
$80.00
$190K-0.25492,483 shs1.00 million shs
SQZ Biotechnologies stock logo
SQZ
SQZ Biotechnologies
$0.02
$0.02
$0.25
▼
$3.56
$708K2.34455,220 shs3,205 shs
Longevity Health Holdings, Inc. stock logo
XAGE
Longevity Health
$0.22
$0.26
$0.21
▼
$2.85
$396K0.42,555 shs4,967 shs
10 Best Stocks to Own - Summer 2026 Cover
10 Best Stocks to Own - Summer 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Atrinsic Inc. stock logo
PTIX
Atrinsic
-10.94%+3.59%+23.17%-50.67%-88.47%
Silexion Therapeutics Corp stock logo
SLXN
Silexion Therapeutics
-8.65%-77.53%-83.71%-85.46%-99.43%
SQZ Biotechnologies stock logo
SQZ
SQZ Biotechnologies
0.00%0.00%0.00%0.00%-14.29%
Longevity Health Holdings, Inc. stock logo
XAGE
Longevity Health
0.00%-30.16%-10.37%-51.72%-90.75%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Atrinsic Inc. stock logo
PTIX
Atrinsic
$0.32
-10.9%		$0.31
$0.13
▼
$6.20
$580K1.0829,810 shs2,477 shs
Silexion Therapeutics Corp stock logo
SLXN
Silexion Therapeutics
$0.42
-8.7%		$2.42
$0.37
▼
$80.00
$190K-0.25492,483 shs1.00 million shs
SQZ Biotechnologies stock logo
SQZ
SQZ Biotechnologies
$0.02
$0.02
$0.25
▼
$3.56
$708K2.34455,220 shs3,205 shs
Longevity Health Holdings, Inc. stock logo
XAGE
Longevity Health
$0.22
$0.26
$0.21
▼
$2.85
$396K0.42,555 shs4,967 shs
10 Best Stocks to Own - Summer 2026 Cover
10 Best Stocks to Own - Summer 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Atrinsic Inc. stock logo
PTIX
Atrinsic
-10.94%+3.59%+23.17%-50.67%-88.47%
Silexion Therapeutics Corp stock logo
SLXN
Silexion Therapeutics
-8.65%-77.53%-83.71%-85.46%-99.43%
SQZ Biotechnologies stock logo
SQZ
SQZ Biotechnologies
0.00%0.00%0.00%0.00%-14.29%
Longevity Health Holdings, Inc. stock logo
XAGE
Longevity Health
0.00%-30.16%-10.37%-51.72%-90.75%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Atrinsic Inc. stock logo
PTIX
Atrinsic
1.00
SellN/AN/A
Silexion Therapeutics Corp stock logo
SLXN
Silexion Therapeutics
2.00
HoldN/AN/A
SQZ Biotechnologies stock logo
SQZ
SQZ Biotechnologies
0.00
N/AN/AN/A
Longevity Health Holdings, Inc. stock logo
XAGE
Longevity Health
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest SLXN, SQZ, PTIX, and XAGE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/29/2026
Silexion Therapeutics Corp stock logo
SLXN
Silexion Therapeutics
Maxim Group logo
Maxim Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
6/15/2026
Silexion Therapeutics Corp stock logo
SLXN
Silexion Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
(Data available from 8/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Atrinsic Inc. stock logo
PTIX
Atrinsic
N/AN/AN/AN/A$1.96 per shareN/A
Silexion Therapeutics Corp stock logo
SLXN
Silexion Therapeutics
N/AN/AN/AN/A$8.33 per shareN/A
SQZ Biotechnologies stock logo
SQZ
SQZ Biotechnologies
$18.16M0.04N/AN/A$1.94 per share0.01
Longevity Health Holdings, Inc. stock logo
XAGE
Longevity Health
$1.05M0.38N/AN/A($6.77) per share-0.03
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Atrinsic Inc. stock logo
PTIX
Atrinsic
-$5.53M-$3.45N/AN/AN/AN/AN/A-379.72%8/18/2026 (Estimated)
Silexion Therapeutics Corp stock logo
SLXN
Silexion Therapeutics
-$11.91M-$80.50N/AN/AN/AN/A-516.86%-176.68%N/A
SQZ Biotechnologies stock logo
SQZ
SQZ Biotechnologies
-$79.46M-$2.61N/AN/AN/A-369.96%-119.83%-59.90%N/A
Longevity Health Holdings, Inc. stock logo
XAGE
Longevity Health
-$10.37M-$4.29N/AN/AN/A-682.67%N/A-261.90%N/A

Latest SLXN, SQZ, PTIX, and XAGE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2026Q2 2026
Silexion Therapeutics Corp stock logo
SLXN
Silexion Therapeutics
-$21.20-$5.17+$16.03-$5.17N/AN/A
5/15/2026Q1 2026
Silexion Therapeutics Corp stock logo
SLXN
Silexion Therapeutics
-$12.90-$0.85+$12.05$8.50N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Atrinsic Inc. stock logo
PTIX
Atrinsic
N/AN/AN/AN/AN/A
Silexion Therapeutics Corp stock logo
SLXN
Silexion Therapeutics
N/AN/AN/AN/AN/A
SQZ Biotechnologies stock logo
SQZ
SQZ Biotechnologies
N/AN/AN/AN/AN/A
Longevity Health Holdings, Inc. stock logo
XAGE
Longevity Health
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Atrinsic Inc. stock logo
PTIX
Atrinsic
N/A
0.29
0.29
Silexion Therapeutics Corp stock logo
SLXN
Silexion Therapeutics
N/A
1.00
1.00
SQZ Biotechnologies stock logo
SQZ
SQZ Biotechnologies
N/A
3.50
3.50
Longevity Health Holdings, Inc. stock logo
XAGE
Longevity Health
N/A
0.47
0.30

Institutional Ownership

CompanyInstitutional Ownership
Atrinsic Inc. stock logo
PTIX
Atrinsic
7.97%
Silexion Therapeutics Corp stock logo
SLXN
Silexion Therapeutics
10.95%
SQZ Biotechnologies stock logo
SQZ
SQZ Biotechnologies
38.51%
Longevity Health Holdings, Inc. stock logo
XAGE
Longevity Health
24.22%

Insider Ownership

CompanyInsider Ownership
Atrinsic Inc. stock logo
PTIX
Atrinsic
8.00%
Silexion Therapeutics Corp stock logo
SLXN
Silexion Therapeutics
4.10%
SQZ Biotechnologies stock logo
SQZ
SQZ Biotechnologies
16.00%
Longevity Health Holdings, Inc. stock logo
XAGE
Longevity Health
29.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Atrinsic Inc. stock logo
PTIX
Atrinsic
21.81 million1.78 millionNot Optionable
Silexion Therapeutics Corp stock logo
SLXN
Silexion Therapeutics
N/A420,000402,000N/A
SQZ Biotechnologies stock logo
SQZ
SQZ Biotechnologies
1,62029.49 million24.77 millionNot Optionable
Longevity Health Holdings, Inc. stock logo
XAGE
Longevity Health
141.78 million1.27 millionN/A

Recent News About These Companies

Longevity Health Announces Routine Board Member Resignation
June 4, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/longevity-health-announces-routine-board-member-resignation?utm_source=marketbeat.com&utm_medium=referral
Head to Head Contrast: Longevity Health (NASDAQ:XAGE) & Biosig Technologies (NASDAQ:STEX)
March 27, 2026  |  defenseworld.netD
Longevity Health Holdings Closes Strategic Investment and Appoints Ram Ajjarapu as Chairman and CEO to Drive Acquisition-Focused Growth
March 17, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/03/17/3257196/0/en/longevity-health-holdings-closes-strategic-investment-and-appoints-ram-ajjarapu-as-chairman-and-ceo-to-drive-acquisition-focused-growth.html
Longevity Health Holdings Ends Merger with True Health
December 12, 2025  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/longevity-health-holdings-ends-merger-with-true-health?utm_source=marketbeat.com&utm_medium=referral
Why Longevity Health Stock Is Skyrocketing Today
July 15, 2025  |  benzinga.comhttps://www.benzinga.com/trading-ideas/movers/25/07/46430331/why-longevity-health-stock-is-skyrocketing-today
Why Longevity Health Stock Is Skyrocketing Today
July 15, 2025  |  benzinga.comhttps://www.benzinga.com/trading-ideas/movers/25/07/46430331/why-longevity-health-stock-is-skyrocketing-today?utm_source=snapi
Why did XAGE Stock Surge in Today’s Premarket Trading?
July 15, 2025  |  tokenist.comT
Longevity Health Holdings, Inc.: Longevity Health Holdings Announces Merger with THPlasma and Termination of 20/20 BioLabs Transaction
July 15, 2025  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2025-07/65907064-longevity-health-holdings-inc-longevity-health-holdings-announces-merger-with-thplasma-and-termination-of-20-20-biolabs-transaction-399.htm
Longevity Health Holdings to Merge With True Health
July 15, 2025  |  marketwatch.comhttps://www.marketwatch.com/story/longevity-health-holdings-to-merge-with-true-health-5632aee0
Longevity Health stock soars after merger with THPlasma in all-stock deal
July 15, 2025  |  investing.comhttps://www.investing.com/news/stock-market-news/longevity-health-stock-soars-after-merger-with-thplasma-in-allstock-deal-93CH-4135554
Longevity Health Holdings Announces Merger with THPlasma and Termination of 20/20 BioLabs Transaction
July 14, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/07/14/3115204/0/en/Longevity-Health-Holdings-Announces-Merger-with-THPlasma-and-Termination-of-20-20-BioLabs-Transaction.html

Media Sentiment Over Time

Atrinsic stock logo

Atrinsic NASDAQ:PTIX

$0.32 -0.04 (-10.94%)
As of 08/14/2026 11:23 AM Eastern

Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics, Inc. is headquartered in New York, New York.

Silexion Therapeutics stock logo

Silexion Therapeutics NASDAQ:SLXN

$0.42 -0.04 (-8.65%)
Closing price 08/14/2026 04:00 PM Eastern
Extended Trading
$0.41 -0.01 (-3.38%)
As of 08/14/2026 07:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel.

SQZ Biotechnologies stock logo

SQZ Biotechnologies NYSE:SQZ

$0.02 0.00 (0.00%)
As of 08/13/2026

SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. The Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.

Longevity Health stock logo

Longevity Health NASDAQ:XAGE

$0.22 0.00 (0.00%)
As of 08/13/2026 02:25 PM Eastern

Carmell Therapeutics Corporation focuses on the development of plasma-based bioactive material (PBM) to stimulate tissue repair or growth after injury, disease, and aging. Its lead product candidate is CT-101 bone healing accelerant for tibia fracture healing, foot/ankle fusion, spinal fusion, dental bone graft substitute, and bone void filler; and tissue healing accelerant for androgenetic alopecia and chronic wound healing. The company was founded in 2008 and is based in Pittsburgh, Pennsylvania.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas